my account
Login
  Loading... Please wait...

New Products

We will continue to add new products to our already extensive portfolio - check back often for the latest breakthroughs. If you can't find what you need, contact us for information on custom synthesis.

 

10-5085

05/20

Remodelin | Acetyltransferase NAT10 inhibitor

Potent and selective inhibitor of N-acetyltransferase 10 (NAT10) which us capable of acetylating microtubules and histones. Improves nuclear architecture, chromatin organization and fitness, normalizing progeric and aging cells.

 

10-3816

05/20

Guggulsterone-(Z) | FXR antagonist

Natural steroid which lowers cholesterol and acts as an FXR antagonist. Induces differentiation of pluripotent stem cells to dopaminergic neurons.

 

10-2822

05/20

Omeprazole | Proton pump inhibitor/ Antiviral

H+,K+-ATPase inhibitor, clinically useful antisecretory and antiulcer agent. Displays broad spectrum antiviral activity and enhances the efficacy of remdesivir.

 

10-5044

05/20

GKT-37831 | NADPH oxidase NOX1/4 inhibitor

GKT137831 inhibits NADPH oxidase BOX1/4 and blocks erastin-stimulated ROS production.

 

 

10-4090

04/20

TIC10 | Mitochondrial caseinolytic protease P activator / Anticancer agent

Novel anti-cancer compound that acts via early-stage integrated stress response activation leading to selective cancer cell death

 

10-4468

04/20

Roxadustat | Proyl hydroxylase domain inhibitor / HIF stabilizer

Pan-prolyl hydroxylase domain (PHD) inhibitor that stabilizes hypoxia-inducible factor (HIF) leading to erythropoiesis.

 

10-4384

04/20

Tiagabine hydrochloride | GABA transporter 1 (GAT1) inhibitor

Clinically useful anticonvulsant that inhibits both neuronal and glial GABA re-uptake

 

10-4471

04/20

Favipiravir | Inhibitor of viral RNA-dependent RNA polymerase

Inhibitor of viral RNA-dependent RNA polymerase with activity against influenza viruses A,B and C as wells as a wide range of other viruses.

 

10-4483

04/20

Oseltamivir Phosphate | Neuraminidase inhibitor / Antiviral

Potent viral neuraminidase inhibitor and clinically useful treatment for influenzas A and B.

 

10-4484

04/20

Ritonavir | HIV1/2 protease inhibitor

Clinically useful HIV-1/HIV-2 protease inhibitor. Potent inhibitor of cytochrome P450 3A4.

 

10-4960

04/20

GRL-0496 | SARS-CoV 3CLpro inhibitor

Potent inhibitor of severe acute respiratory syndrome-coronavirus chymotrypsin-like protease.

 

10-4965

04/20

GRL-0617 | Potent SARS-CoV PLpro inhibitor

Potent noncovalent inhibitor of severe acute respiratory syndrome-coronavirus papain-like protease. Inactive against human DUB-like proteases.

 

10-3050

04/20

Nelfinavir mesylate | HIV protease inhibitor / Anticancer activity

Clinically useful anti-HIV acting via inhibition of HIV-1 proteases. Also displays efficacy in cancer, malaria, tuberculosis and SARS.

 

10-3474

04/20

Prochlorperazine maleate | Endocytosis inhibtior

Inhibits dynamin and clathrin-mediated endocytosis. Increases tumor cell antigen presentation.

 

10-4032

04/20

Tazemetostat | EZH2 inhibitor

Potent and selective SAM-competitive inhibitor of the lysine methyltransferase EZH2

 

10-5064

04/20

Ponatinib | Bcr-Abl multikinase inhibitor

Highly potent pan-Bcr-Abl and multikinase inhibitor, suppressing the activity of native Bcr-Abl as well as the mutants T315I, Q252H, Y253F, M351T and H396P. Protects against influenza A virus-induced death by suppressing cytokine storm in mouse models.

 

10-3613

03/20

Santacruzamate A | Ultrapotent HDAC2 inhibitor

Highly potent and selective inhibitor of HDAC2 isolated from the Panamanian marine cyanobacterium cf. Symploca.

 

10-3965

03/20

Brequinar sodium | Dihydroorotate dehydrogenase inhibitor, antiviral

Inhibitor of dihydroorotate dehydrogenase with broad antiviral activity against flaviviruses, positive-strand RNA alphaviruses, negative-strand RNA rhabdoviruses, influenza A and B viruses and HIV.

 

10-5046

03/20

Roxatidine | Histamine H2 antagonist, antiulcer, anti-inflammatory

Novel histamine H2 receptor antagonist that suppresses inflammatory response via inhibition of NF&kappa>B and p38 MAPK activation in macrophages.

 

10-3970

03/20

N4-Hydroxycytidine | Novel antiviral

N4-Hydroxycytidine is the active molecule in the antiviral pro-drug clinical candidate EIDD-2801 with action against a broad range of viruses including coronaviruses

 

10-2196

03/20

Camostat mesylate | Serine protease inhibitor, antiviral, anti-inflammatory activity

Reduces infection of Calu-3 lung cells by SARS-CoV-2 (responsible for COVID-19) via inhibition of the serine protease TMPRSS2 required for viral spike protein priming.

 

10-2712

03/20

Scriptaid | HDAC inhibitor

Inhibits HDACs 1,3 and 8. Induces cell cycle arrest and epigenetic changes in colon cancer cells.

 

10-2790

03/20

Dihydroresveratrol | Resveratrol metabolite

Glucuronide conjugates of dihydroresveratrol are found in human urine after oral intake of resveratrol dietary supplements.

 

10-1561

03/20

DY131 | Estrogen-related receptor ERRβ and ERRγ agonist

Selective agonist at estrogen-related receptors ERRβ and ERRγ with minimal activity at ERRα, ERα and ERβ. Displays antiproliferative activity in prostate cancer cells.

 

10-3960

03/20

PK150 | Sorafenib analog with unique antibacterial properties

Displays significant antibacterial activity against S. aureus NSTC8325, vancomycin-resistant enterococci and M. tuberculosus. Inactive against Gram-negative bacteria

 

10-2955

03/20

Leelamine | Intracellular cholesterol inhibitor

Induces cholesterol accumulation in lysosomal/endosomal cell compartments via inhibition of autophagic flux

 

10-4810

02/20

NU7441 | DNA-PK inhibitor

Potent and selective ATP-competitive inhibitor of DNA-dependent protein kinase. Increases radio/chemosensitivity of various cancer cell lines.

10-4810

02/20

Crenolanib | PDGF and FLT3 inhibitor

Potent inhibitor of PDGFR and FLT3 that binds only to the active kinase configuration.

10-4778

02/20

AZ3146 | Mps 1kinase inhibitor

Potent and selective inhibitor of monopolar spindle 1 that decreases hepatocellular carcinoma growth in vitro.

10-4771

02/20

AZD7762 | Checkpoint Kinase 1/2 inhibitor

Potent and selective inhibitor of checkpoint kinases 1 and 2. It abrogates DNA damage-induced S and G2 checkpoints and enhances the efficacy of DNA damaging agents such as gemcitabine and irinotecan.

10-4779

02/20

SNS-314 mesylate | Aurora kinase inhibitor

Potent and selective Aurora kinase inhibitor. Able to inhibit proliferation in a wide panel of human cancer cell lines.

10-3901

02/20

Elafibranor | PPARalpha/delta agonist

Able to decrease plasma triglycerides levels, increase HDL cholesterol levels in human studies, and improve hepatic and peripheral insulin sensitivity.

10-2040

02/20

Levetiracetam | Anticonvulsant

Clinically useful non classical anticonvulsant believed to act through binding to SV2A. No effect on voltage-dependent Na+ channels, GABAergic transmission, or affinity for either GABAergic or glutaminer rgic eceptor.

10-3900

02/20

Tigecycline | Antibiotic

Clinically useful antibiotic that has also been shown to be selectively toxic to human acute myeloid leukemia cells over normal hematopoietic cells.

10-4818

02/20

Volasertib | Potent and selective inhibitor of Polo-like kinase 1

Potent and selective inhibitor of Polo-like kinase 1 that has shown efficacy in multiple solid xenograft tumor models and in clinical studies of patients with acute myeloid leukemia.

10-4784

02/20

Fruquintinib | Potent and selective inhibitor of VEGFR kinase

Potently and selectively inhibits VEGF/VEGFR signaling and cell proliferation in HUVECs and HLECs and prevents angiogenesis in vitro.

10-4675

02/20

AZ20 | ATR kinase inhibitor

Combination therapy with AZ20 and gemcitabine resulted in synergistic inhibition of tumor cell growth and cell death initiation in pancreatic cancer cell lines.

10-4804

02/20

AZD1152-HQPA | Aurora B kinase inhibitor

Highly selective inhibitor of Aurora kinase B that inhibits the growth of tumors in multiple cancer models.

10-4017

02/20

Lomeguatrib | MGMT inhibitor

Potent inhibitor of O6-Methylguanine-DNA Methyltransferase (MGMT), an important DNA repair protein.

10-4531

02/20

Methoprene Acid | Selective RXR agonist

Binds directly and selectively to the retinoid X receptor (RXR) acting as a transcriptional activator with no activity at RAR. Negatively regulates thrombosis and hemostasis.

10-3648

02/20

ML-335 | Trek-1,2 activator

Novel, selective TREK-1,2 activator with EC50s of 14.3 and 5.2 µM

10-3756

02/20

NOTUMib-1 | NOTUM inhibitor, restores Wnt signaling

Inhibits the carboxylesterase activity of NOTUM, IC50=0.085 µM, and restores Wnt signaling.

10-1525

02/20

MitoBloCK-12 | Mitochondrial import inhibitor

Blocks translocation of a mutant form of alanine: glyoxylate aminotransferase (AGT) to the mitochondria and restores AGT trafficking to peroxisomes.

10-3631

02/20

N-Eicosanoyl serotonin | Neuroprotective

Inhibits the PP2A methylesterase maintaining PP2A in a highly active state leading to hyperphosphorylat αed -synuclein.

10-3712

02/20

DO264 | ABHD12 inhibitor

Potent, reversible competitive inhibitor of ABHD12 (α/β-hydrolase domain-containing 12) which shows negligible interaction with other serine hydrolases.

10-3321

02/20

Rucaparib phosphate | PARP1 inhibitor

Potent PARP1 inhibitor. Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2.

10-2768

02/20

Pomalidomide | Cereblon ubiquitination inhibitor

Inhibits the E3 ubiquitin ligase cereblon (CRBN). Displays antiangiogenic and immunomodulatory activity in vivo potently inhibiting the production of TNF alpha and IL-2.

10-4230

02/20

Imiquimod | TLR7 agonist

Toll-like receptor 7/8 agonist with anti-viral and anti-tumor properties. Enhances innate immune system leading to Th1-mediated antitumor immune response.

10-2671

02/20

Norfluoxetine HCl | Fluoxetine Metabolite

Induces long QT syndrome via slow delayed rectifier potassium current block. Time dependent inhibitor of CYP2C19 and CYP3A4.

10-4806

02/20

Acalabrutinib | Highly selective BTK inhibitor

Hghly selective, potent (IC50 = 3nM), and irreversible inhibitor of Bruton’s tyrosine kinase (BTK). Significantly inhibits BCR signaling, inhibits tumor proliferation, and reduces tumor burden.

10-4757

02/20

Ibrutinib | BTK inhibitor

Very potent (IC50 = 0.5nM) irreversible inhibitor of Bruton tyrosine kinase (BTK) that blocks activation of the B-cell antigen receptor (BCR).

Focus BiomoleculesPlymouth Meeting, PA USA1-855-FOCUS21

Connect with Focus